Crinetics Pharmaceuticals, Inc.

Contributing Author

Recent Articles by Crinetics Pharmaceuticals, Inc.

3 hours	Crinetics Initiates Phase 2/3 Pediatric Trial Evaluating Atumelnant in Congenital Adrenal Hyperplasia (CAH) CRNX GlobeNewswire
Jan-12	Crinetics Pharmaceuticals Announces January 2026 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CRNX GlobeNewswire
Jan-06	Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock CRNX GlobeNewswire
Jan-05	Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock CRNX GlobeNewswire
Jan-05	Crinetics Announces Strong PALSONIFY Launch Execution and Positive Results for Concurrent Androstenedione Lowering and Glucocorticoid Dose Reduction in Phase 2 Trial of Atumelnant for Congenital Adrenal Hyperplasia CRNX GlobeNewswire
Jan-04	Crinetics Pharmaceuticals to Provide PALSONIFY Business Update and Announce Topline Results from Fourth Cohort of Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia CRNX GlobeNewswire
Dec-18	Crinetics Pharmaceuticals to Participate in The 44th Annual J.P. Morgan Healthcare Conference CRNX GlobeNewswire
Dec-11	Crinetics Announces First Patient Dosed in Pivotal Adult Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) CRNX GlobeNewswire
Dec-10	Crinetics Pharmaceuticals Announces December 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CRNX GlobeNewswire
Dec-03	Crinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and Other Somatostatin Receptor 2-Expressing Tumors CRNX GlobeNewswire
Nov-20	Crinetics Announces First Patient Randomized in Pivotal Phase 3 CAREFNDR Trial Evaluating Paltusotine in Carcinoid Syndrome CRNX GlobeNewswire
Nov-10	Crinetics Pharmaceuticals Announces November 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CRNX GlobeNewswire
Nov-06	Crinetics Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update CRNX GlobeNewswire
Oct-23	Crinetics to Highlight Neuroendocrine Tumor Research Progress at the 2025 North American Neuroendocrine Tumor Society Annual Meeting CRNX GlobeNewswire
Oct-10	Crinetics Pharmaceuticals Announces October 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CRNX GlobeNewswire
Oct-06	Crinetics Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025 CRNX GlobeNewswire
Sep-25	Crinetics Announces FDA Approval of PALSONIFY (paltusotine) for the Treatment of Adults with Acromegaly CRNX GlobeNewswire
Sep-10	Crinetics Pharmaceuticals Announces September 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CRNX GlobeNewswire
Aug-21	Crinetics Receives FDA Orphan Drug Designation for Atumelnant in the Treatment of Congenital Adrenal Hyperplasia (CAH) CRNX GlobeNewswire
Aug-11	Crinetics Pharmaceuticals Announces August 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CRNX GlobeNewswire
Aug-07	Crinetics Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update CRNX GlobeNewswire
Jul-13	Crinetics to Present New Long-Term Data Demonstrating Durable Control of Once-Daily, Oral PALSONIFY (Paltusotine) in Acromegaly at ENDO 2025 CRNX GlobeNewswire
Jul-11	Crinetics Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025 CRNX GlobeNewswire
Jul-10	Crinetics Pharmaceuticals Announces July 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CRNX GlobeNewswire
Jun-30	Crinetics to Showcase the Next Generation of Endocrinology Innovation at ENDO 2025 with Eight Presentations From its Deep Pipeline CRNX GlobeNewswire
Jun-16	Crinetics Pharmaceuticals to Host R&D Day on June 26, 2025 CRNX GlobeNewswire
Jun-10	Crinetics Pharmaceuticals Announces June 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CRNX GlobeNewswire
May-23	Crinetics Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2025 CRNX GlobeNewswire
May-15	Crinetics to Present New Research on Paltusotine, Atumelnant and Unmet Needs in Acromegaly Treatment at the American Association of Clinical Endocrinology Annual Meeting 2025 CRNX GlobeNewswire
May-12	Crinetics Pharmaceuticals Announces May 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CRNX GlobeNewswire
May-08	Crinetics Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update CRNX GlobeNewswire

Crinetics Pharmaceuticals, Inc.

Recent Articles by Crinetics Pharmaceuticals, Inc.

Upgrade your FINVIZ experience